XML 59 R4.htm IDEA: XBRL DOCUMENT v2.4.1.9
Consolidated Statements of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Revenues:      
Product sales $ 308,345us-gaap_SalesRevenueGoodsNet $ 257,922us-gaap_SalesRevenueGoodsNet $ 215,879us-gaap_SalesRevenueGoodsNet
Contract manufacturing 30,944ebs_ContractManufacturing 0ebs_ContractManufacturing 0ebs_ContractManufacturing
Contracts, grants and collaborations 110,849us-gaap_ContractsRevenue 54,823us-gaap_ContractsRevenue 66,009us-gaap_ContractsRevenue
Total revenues 450,138us-gaap_SalesRevenueNet 312,745us-gaap_SalesRevenueNet 281,888us-gaap_SalesRevenueNet
Operating expenses:      
Cost of product sales 118,412us-gaap_CostOfGoodsSold 62,127us-gaap_CostOfGoodsSold 46,077us-gaap_CostOfGoodsSold
Research and development 150,829us-gaap_ResearchAndDevelopmentExpense 119,933us-gaap_ResearchAndDevelopmentExpense 120,226us-gaap_ResearchAndDevelopmentExpense
Selling, general and administrative 122,841us-gaap_SellingGeneralAndAdministrativeExpense 87,883us-gaap_SellingGeneralAndAdministrativeExpense 76,018us-gaap_SellingGeneralAndAdministrativeExpense
Impairment of in-process research and development 0us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill 0us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill 9,600us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Income from operations 58,056us-gaap_OperatingIncomeLoss 42,802us-gaap_OperatingIncomeLoss 29,967us-gaap_OperatingIncomeLoss
Other income (expense):      
Interest income 320us-gaap_InvestmentIncomeInterest 139us-gaap_InvestmentIncomeInterest 134us-gaap_InvestmentIncomeInterest
Interest expense (8,240)us-gaap_InterestExpense 0us-gaap_InterestExpense (6)us-gaap_InterestExpense
Other income (expense), net 2,926us-gaap_OtherNonoperatingIncomeExpense 426us-gaap_OtherNonoperatingIncomeExpense 1,970us-gaap_OtherNonoperatingIncomeExpense
Total other income (expense) (4,994)us-gaap_NonoperatingIncomeExpense 565us-gaap_NonoperatingIncomeExpense 2,098us-gaap_NonoperatingIncomeExpense
Income before provision for income taxes 53,062us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 43,367us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments 32,065us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Provision for income taxes 16,321us-gaap_IncomeTaxExpenseBenefit 13,108us-gaap_IncomeTaxExpenseBenefit 13,922us-gaap_IncomeTaxExpenseBenefit
Net income 36,741us-gaap_ProfitLoss 30,259us-gaap_ProfitLoss 18,143us-gaap_ProfitLoss
Net loss attributable to noncontrolling interest 0us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 876us-gaap_NetIncomeLossAttributableToNoncontrollingInterest 5,381us-gaap_NetIncomeLossAttributableToNoncontrollingInterest
Net income attributable to Emergent BioSolutions Inc. $ 36,741us-gaap_NetIncomeLoss $ 31,135us-gaap_NetIncomeLoss $ 23,524us-gaap_NetIncomeLoss
Earnings per share - basic (in dollars per share) $ 0.98us-gaap_EarningsPerShareBasic $ 0.86us-gaap_EarningsPerShareBasic $ 0.65us-gaap_EarningsPerShareBasic
Earnings per share - diluted (in dollars per share) $ 0.88us-gaap_EarningsPerShareDiluted $ 0.85us-gaap_EarningsPerShareDiluted $ 0.65us-gaap_EarningsPerShareDiluted
Weighted-average number of shares - basic (in shares) 37,344,891us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 36,201,283us-gaap_WeightedAverageNumberOfSharesOutstandingBasic 36,080,495us-gaap_WeightedAverageNumberOfSharesOutstandingBasic
Weighted-average number of shares - diluted (in shares) 45,802,807us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 36,747,556us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding 36,420,662us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding